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The bone marrow failure syndrome Dyskeratosis congenita 
(DC), though rare, has attracted a great deal of attention in the 
last few years because it is caused by mutations in genes whose 
products are involved in telomere maintenance. The disease 
presents with a variety of features that can all be due to failure 
of tissues that require constant renewal via stem cell activity. It is 
thought this is caused by defects in telomere maintenance leading 
eventually to cell cycle arrest or cell death caused by critically short 
telomeres. The most common form of DC is the X-linked form 
caused by mutations in DKC1 encoding the nucleolar protein, 
dyskerin. We recently reported a mouse model of the X-linked 
form of the disease in which females heterozygous for a muta-
tion that copies a human pathogenic mutation showed a growth 
disadvantage in cells expressing the mutant dyskerin. This growth 
disadvantage, which was associated with an enhanced DNA 
damage response, was dependent on telomerase but appeared to 
be independent of telomere shortening. Here we discuss these 
results in terms of the role of dyskerin in telomere maintenance 
and the possible role that the DNA damage response plays in the 
pathogenesis of DC.
Introduction
Telomere homeostasis is important in cancer, where nearly 
all tumors require increased levels of telomerase to counteract 
the telomere shortening that takes place with each cell division.1 
Telomere maintenance may also be important in aging, since 
telomere shortening in somatic cells, which express no or little telom-
erase, means that these cells have a finite number of cell divisions 
before critically short telomeres drive the cells into senescence in a 
process known as replicative aging.2,3 The role of telomere short-
ening in organismal aging is controversial. In dyskeratosis congenita 
we have the opportunity to observe the effects of defective telomere 
maintenance in humans, and the role of telomere maintenance in 
cancer and aging.
The Genetics of Dyskeratosis Congenita
Dyskeratosis congenita is genetically diverse with autosomal reces-
sive and dominant and X-linked pedigrees having been described 
(Table 1). The major X-linked form is due to mutations in the 
DKC1 gene which encodes the 57 kD protein dyskerin.4 Dyskerin 
is a highly conserved nucleolar protein that, as part of a specialized 
nucleolar RNP, catalyses the pseudouridylation of specific residues 
in newly synthesized ribosomal RNAs and spliceosomal snRNAs.5 
Dyskerin also associates with telomerase,6 and since products of 4 
other genes whose mutation causes DC also associate with telomerase 
it is thought that telomerase defects underlie the DC phenotype. 
These other genes are NOP10,7 NHP2 (recessive),8 TERC9 and 
TERT10 (dominant). NOP10 and NHP2 are associated with dysk-
erin in both the RNP complex and in telomerase while TERC is the 
telomerase RNA template and TERT is the telomerase reverse tran-
scriptase. A sixth gene causing DC, TINF2,11,12 encodes a protein 
TIN2,13 that is not part of telomerase but is one of the protein 
components of shelterin, a protein complex associated with telomere 
DNA at the ends of chromosomes.14
Molecular Pathology
Dyskeratosis congenita, though classically defined by a triad of 
mucocutaneous features (skin pigmentation abnormalities, leuko-
plakia and nail dystrophy) usually involves bone marrow failure 
which is often the cause of death. It is always associated with very 
short telomeres that are shorter than the first percentile of telomere 
lengths seen in the normal population.15 DC mutations have also 
been found in patients with aplastic anemia16 and pulmonary 
fibrosis17,18 leading to a less restricted definition of the disease. 
Expression of the disease, which correlates to some extent with the 
gene mutation, (Table 1) varies between very severe presentation in 
children below 1 to mild anemia in old age. It is generally accepted 
that the defects in DC are caused by increased rates of telomere 
shortening in adult stem cells leading to failure of cell renewal and 
thereby causing bone marrow failure, pulmonary fibrosis and the 
other manifestations of DC, which include an increased suscep-
tibility to cancer. In X-linked DC there is good evidence that 
the mutations in dyskerin lead to destabilization of TERC and a 
decrease in telomerase activity.19 In this X-linked condition female 
carriers of the disease usually show 100% skewing of X-inactivation, 
at least in white blood cells.20,21 At an early stage of embryonic 
development in female placental mammals one X-chromosome is 
inactivated in every cell. It is random whether in any given cell the 
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the differences in expression at the protein level were reflected in 
differences in mRNA levels. The growth advantage was greater in 
hematopoietic tissues such as spleen and bone marrow but was also 
evident in less proliferative tissues such as liver. Part of the rationale 
for our experimental approach was that mice would not be expected 
to show any phenotype due to telomere shortening in the first gener-
ation. This was based on the observations that mice that are null 
for telomerase RNA, (Terc-/-)26 or telomerase reverse transcriptase 
(Tert-/-)27 do not show a phenotype at first but after inbreeding for 
several generations show a phenotype with similarities to human 
DC. This is because laboratory mice have very long telomeres and 
several generations in the absence of telomerase are required before 
telomeres reach a critically short length. Surprisingly, however, when 
we tested Dkc1D15/+Terc-/- or Dkc1D15/+Tert-/- mice no growth advan-
tage was evident. The growth advantage was also partially rescued in 
Dkc1D15/+p53-/- mice. Together these results suggested that cells with 
the Dkc1D15 mutation exhibit slower growth than wild type cells and 
that this was dependent on telomerase, was independent of telomere 
length and was mediated, at least in part via p53.
paternal or maternal X is inactivated.22,23 Thereafter in carriers of 
a DKC1 mutation there will be 2 types of cell, one with wild type 
and one with mutant dyskerin, and cells with wild type dyskerin 
must outgrow those with mutant dyskerin leading to only one type 
of cell in the adult.
A Mouse Model of X-linked DC
We have made a mouse model of X-linked DC24 by recreating 
in the mouse a mutation that causes DC in an X-linked family,25 a 
deletion of exon 15 that leads to a truncation of the dyskerin protein 
by 22 amino acids in human and 21 amino acids in mouse. This 
deletion had the advantage that we were able to distinguish between 
the wild type and mutant protein on Western blots. Male mice 
carrying the deletion, Dkc1D15, did not show any obvious phenotype 
but in female heterozygous mice, Dkc1D15/+, expression of the two 
proteins was unequal in older mice with greater expression of the 
wild type protein. We reasoned that this was most likely due to a 
growth advantage enjoyed by the cells expressing wild type dyskerin 
after random X-inactivation. This was supported by the fact that 
Table 1 Characteristics of genes mutated in dyskeratosis congenita
Gene Gene product Chromosomal Function Types of mutation Clinical presentation References 
  location
DKC1 Dyskerin Xq28 Pseudouridine synthase.  Mainly mis-sense. X-linked recessive. 4, 45 
   Component of H/ACA Common recurrent Dyskeratosis congenita (DC) 
   RNP and telomerase mutation 40% of varying in severity.  
   complex X-linked cases is A353V. The more severe variant 
    Null mutations Hoyeraal-Hreidarrson syndrome 
    probably lethal (HH) characterized by 
     intra-uterine growth 
     retardation, immune deficiency 
     and cerebellar hypoplasia.
TINF2 TIN2—TRF1 interacting 14q12 Component of shelterin Mainly missense Autosomal dominant. 11, 12 
 factor 2  complex at telomeres clustered at aa Usually sporadic. 
    280–291 with DC, HH, AA and Revesz 
    two thirds syndrome, severe bone 
    affecting marrow failure with 
    residue 282. retinopathy. Nearly 
    Some frameshifts. always severe.
TERC Telomerase RNA 3q21-q28 RNA component of All types, deletions,  Autosomal dominant.  16–18,  
 component  telomerase—provides point mutations etc. Wide variety of presentation 45, 46 
   template for synthesis of  including DC, aplastic anemia, 
   telomere repeats  pulmonary fibrosis, MDS. 
     Variable penetrance.
TERT Telomerase reverse 5p15.33 Telomerase reverse All types, deletions,  Autosomal dominant. 10, 17,  
 transcriptase  transcriptase—synthesizes point mutations etc. Rarely autosomal recessive. 18, 43,  
   telomere repeats  Wide variety of presentation 45,  
     including DC, aplastic anemia, 47–49 
     pulmonary fibrosis, MDS. 
     Variable penetrance.
NOP10 NOP10—Nucleolar 15q14-q15 Component of H/ACA 1 missense mutation described Autosomal recessive.  7 
 protein 10  RNP and telomerase in 1 family with 3 Mild dyskeratosis congenita,  
   complex homozygous affected siblings low penetrance of 
     aplastic anemia.
NHP2 NHP2—Non-histone Chr 5 Component of H/ACA 2 patients have been Autosomal recessive.  8 
 chromosome protein 2  RNP and telomerase described—1 homozygous Both patients had 
   complex for a missense mutation and the classical dyskeratosis 
    other compound heterozygous congenita 
    for a missense and 
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DC like phenotype was observed in male mice suggesting that the 
lower proliferation rate is not sufficient to impact on tissue renewal, 
at least in one generation. The assay we use to assess comparative 
proliferation rate, namely competitive growth of cells in a female 
mosaic after random X-inactivation may be very sensitive. Indeed if 
32 cell divisions are required for the growth39 of an early embryo into 
an adult mouse then a 5% increase in the time between cell divisions 
will lead to an approximately 80% reduction in the number of the 
slower growing cells. Such a small reduction in growth rate, while 
easy to see in the competitive situation, may not affect the growth 
and development of males. Another factor here may be differences 
between mouse and humans in the detailed mechanisms of both 
telomere maintenance40,41 and stem cell function.
Of the six genes so far identified as causing DC, two of them— 
NOP107 and NHP28— have been found to be very rare and present 
in one or a handful of families. The others fall into two groups 
in terms of presentation and penetrance. Mutations in TERT 10 
and TERC15 have less than 100% penetrance and generally show 
anticipation with increased severity and earlier age of onset in later 
generations.42,43 This is likely due to the fact that later generations 
inherit shortened telomeres from the affected parent as well as 
the pathogenic mutation. Mutations in DKC1,4 and TINF2,11,12 
however exert their effects in generation 1 where they usually cause 
severe aplastic anemia and dyskeratosis congenita of varying severity, 
with TINF2 mutations perhaps being on average more severe. The 
difference between these two groups may be that TERC and TERT 
mutations lead to telomere shortening with no consequences until a 
critically short telomere length is reached whereas DKC1 and TINF2 
mutations in addition cause cell death via the p53 DNA damage 
pathway due to telomere defects independent of telomere length 
and thus exert their effects in generation 1. Supporting this idea is 
our finding of a DNA damage response in mice with a pathogenic 
Dkc1 mutation.24 While the TINF2 pathogenic mutations have not 
yet been shown to elicit a DNA damage response at telomeres other 
TIN2 mutations, that destabilize shelterin components TRF1 and 
TRF2 do induce DNA damage.44 All DC patients however have 
very short telomeres but whether short telomeres are always causative 
of the disease or are a consequence of increased replicative telomere 
erosion is not clear. Thus it is possible that the DNA damage caused 
by these mutations contributes to bone marrow failure by leading 
to increased rate of recruitment of stem cells and eventual stem cell 
exhaustion (Fig. 1).
Summary and Future Prospects
In summary the finding of an increased DNA damage response 
in mice with a pathogenic mutation in Dkc1 has important implica-
tions for the role of dyskerin in telomere maintenance. Coupled with 
the recent finding of DC due to TINF2 mutations it suggests that 
failure to maintain telomere integrity in DC may arise by more than 
one pathway. It will now be important to work out precisely how 
dyskerin and TIN2 interact with other components of telomerase 
and of shelterin to bring about the exquisite control of telomere 
homeostasis needed to strike the essential balance between aging and 
malignancy.
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Mutant Dyskerin Affects the DNA Damage Response
The involvement of p53 in the reduced growth of cells with a 
mutant dyskerin implicates a DNA damage responsive cell cycle 
checkpoint in the phenomenon and indeed male Dkc1D15 MEF cells 
were shown to have an enhanced DNA damage response following 
etoposide treatment. Both wild type and mutant cells showed an 
increase in DNA damage foci containing g-H2AX, a phosphorylated 
histone that appears rapidly at sites of DNA damage,28 especially 
double stranded breaks. Furthermore many of the DNA damage foci 
co-localized with telomeres in the mutant but not the wild type cells.
These findings, implicating a hitherto unknown pathway, raise 
many new questions, in particular:- What is the role of dyskerin and 
telomerase in the DNA damage response? Is the reduction in growth 
and increased DNA damage response important in the pathogenesis 
of X-linked DC?
Dyskerin and Telomerase in the DNA Damage Response 
Pathway?
Telomere maintenance and the DNA damage response are closely 
connected with many of the proteins involved in the DNA damage 
response also playing important roles in telomere maintenance.29 It 
is well known that critically short telomeres induce a p53 dependent 
DNA damage response that, if unresolved, may lead to cell cycle 
arrest and senescence or apoptosis.30 Indeed the accepted view of 
the pathogenesis of DC is that defects in telomerase lead to acceler-
ated telomere shortening and eventually to short telomere induced 
senescence/apoptosis in stem cells. As well as telomere length defec-
tive telomere structure may also cause a DNA damage response.31 
Moreover a transient DNA damage response is thought to occur at 
telomeres during replication.32 Since telomere elongation and repli-
cation are presumably tightly coupled33 it is likely that defects in 
elongation may enhance this response. Although dyskerin is thought 
to be involved chiefly in the assembly of the functional telomerase 
complex its presence in purified active telomerase34 may suggest it 
plays an important role in telomerase action. On this model mutant 
dyskerin may affect the access of telomerase to its substrate or the effi-
ciency of telomerase activity and lead to a dysfunctional telomere.
Another possibility is that telomerase has a cellular function not 
dependent on telomere length and it is this function that is affected by 
mutant dyskerin, leading to the DNA damage response. Suggestions 
that telomerase has a telomere length independent function in 
mice arise from observations that overexpression of telomerase can 
promote tumorigenesis in mice with perfectly long telomeres35,36 and 
conversely that lack of telomerase can suppress chemically induced 
carcinogenesis in long telomere mice.37 In addition in human cells 
hTERT was shown to contribute to tumorigenesis in the absence of 
any effect on telomere length maintenance.38 The mechanism of this 
length independent role of telomerase and its connection with DNA 
damage at telomeres remains to be determined.
Possible Importance of the DNA Damage Response in the 
Pathogenesis of X-Linked DC
Is the induction of the DNA damage response an important 
factor in the pathogenesis of dyskeratosis congenita? In the Dkc1D15/+ 
heterozygous female mice the induction of the DNA damage 
response was associated with decreased proliferation. However no 
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